Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1608)	10/21/2005 11:57:22 AM
From: tom pope	Read Replies (1) \| Respond to of 1826

I don't remember whether I posted this snippet from yesterday's Merrill Morning Call or not: MGI Pharma (MOGN, $22.82, C-1-9) Reiterate Buy and $28 PT. Q3 Results: Lowering 05E to $0.36 from $0.53 & 06E to $0.59 from $0.92 due to Higher Spending. 3Q in-line w/ preannounced guidance. Importantly, collected all required transfusion data from the phase III Dacogen study - should enable an NDA re-filing by 11/15. Also, the Aquavan phase II dosing study is fully enrolled with data expected by YE05 and a pivotal trial starting in early ‘06. Guided large launch expenses for Dacogen, & R&D spending for Aquavan’s phase III trial along w/ pipeline products (Aloxi for PONV, Dacogen for AML, & ZYC101a).